These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30102655)

  • 1. Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.
    Koehn J; Iwamoto JF; Kraft JC; McConnachie LA; Collier AC; Ho RJY
    AIDS; 2018 Nov; 32(17):2463-2467. PubMed ID: 30102655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
    Kraft JC; McConnachie LA; Koehn J; Kinman L; Collins C; Shen DD; Collier AC; Ho RJ
    AIDS; 2017 Mar; 31(6):765-770. PubMed ID: 28099191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
    Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
    J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
    McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
    J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
    Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
    J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.
    Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
    AIDS; 2014 Nov; 28(17):2625-7. PubMed ID: 25102089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products.
    Perazzolo S; Shen DD; Scott AM; Ho RJY
    J Pharm Sci; 2024 Jun; 113(6):1653-1663. PubMed ID: 38382809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
    Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs.
    Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J
    J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
    Perazzolo S; Stephen ZR; Eguchi M; Xu X; Delle Fratte R; Collier AC; Melvin AJ; Ho RJY
    AIDS; 2023 Nov; 37(14):2131-2136. PubMed ID: 37650755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
    Perazzolo S; Shen DD; Ho RJY
    J Pharm Sci; 2022 Mar; 111(3):825-837. PubMed ID: 34673094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
    von Bibra M; Rosenkranz B; Pretorius E; Rabie H; Edson C; Lenker U; Cotton M; Klinker H
    Paediatr Int Child Health; 2014 May; 34(2):138-41. PubMed ID: 24225343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101.
    Perazzolo S; Shireman LM; McConnachie LA; Koehn J; Kinman L; Lee W; Lane S; Collier AC; Shen DD; Ho RJY
    J Pharm Sci; 2020 May; 109(5):1789-1801. PubMed ID: 32006525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
    Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
    HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids.
    Barreiros L; Cunha-Reis C; Silva EMP; Carvalho JRB; das Neves J; Sarmento B; Segundo MA
    J Pharm Biomed Anal; 2017 Mar; 136():120-125. PubMed ID: 28073073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.
    Pressiat C; Amorissani-Folquet M; Yonaba C; Treluyer JM; Dahourou DL; Eboua F; Blanche S; Mea-Assande V; Bouazza N; Foissac F; Malateste K; Ouedraogo S; Lui G; Leroy V; Hirt D
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.